Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
PFF program to aid people with new pulmonary fibrosis diagnosis. The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis.
PFF program seeks to to aid pulmonary fibrosis patients with new...
4 days ago · The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Some helpful hacks for those living with IPF November 19, 2024; MNKD-201, inhaled nintedanib for IPF, found safe in healthy people November 15, 2024; To my IPF community: Now is the time for legislative advocacy November 12, 2024; Potential pulmonary fibrosis therapy CAL101 fares well in study November 8, 2024; Now you know: Updates from my journey living with IPF November 5, 2024
New prototype therapy may repair IPF lung scarring by …
Apr 26, 2024 · The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial that’s evaluating CMR316, an investigational inhalable therapy similar to the designed prototype. “Most drugs act by slowing the progression of disease; our approach is to make drugs that control cell fate to stop or reverse the disease process,” Peter G. Schultz, PhD, president and CEO of Scripps ...
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
Sep 27, 2024 · FIBRONEER-IPF (NCT05321069) enrolled 1,177 patients, ages 40 and older, at several sites in the U.S., Canada, South America, Europe, Asia, and Australia. Full efficacy and safety data will be presented in the first half of 2025. The company intends to seek the nerandomilast’s approval for IPF to the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide.
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary clinical evidence showing the investigational therapy may improve at least one clinically relevant outcome significantly, compared with available therapies.
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a 1.1% increase in the placebo.
Bexotegrast reverses signs of IPF lung scarring in Phase 2a trial
May 17, 2024 · The Phase 2a imaging study (NCT05621252) enrolled 10 IPF patients. Participants were randomly assigned, with seven receiving 160 mg of once-daily bexotegrast, and three given a matching placebo for 12 weeks.
What Is Pulmonary Fibrosis?
Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung conditions collectively known as interstitial lung diseases (ILDs), many of which are known to cause progressive fibrosis.. Types and causes of PF. In …
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
Sep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased by 62% with treatment at that dose.. Study results support moving BMS-986278 into global Phase 3 testing in a trial program being called ALOFT, according to the therapy’s developer, Bristol ...